AGP Picks
View all

Immunophotonics Strengthens U.S. Intellectual Property Position

News originally published by

EIN Presswire

New U.S. patent covers IP-001 in combination with immune-checkpoint inhibitors and builds on protection already granted in other key jurisdictions

SAINT LOUIS, MO, UNITED STATES, November 19, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on developing novel immunostimulatory therapies to enhance routine tumor destruction treatments, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,797,407, titled “Semi-Synthetic Biopolymers for Use in Stimulating the Immune System.” The patent strengthens the company’s intellectual property portfolio and provides additional U.S. protection for its proprietary technology.

The patent includes claims covering the combination of IP-001 with immune-checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 therapies, which are currently among the most widely used and best-selling cancer therapeutics. The patent was also granted a 584-day Patent Term Adjustment, extending its term into 2041, which prolongs the duration of the company’s intellectual property protection for this combinational approach and strengthens IP-001's future commercialization potential.

The obtained patent claims are part of Immunophotonics’s strategy to build a robust and strategically layered patent portfolio around its proprietary platform and lead clinical asset, IP-001. This U.S. patent is the national-stage application of the same patent family that was granted earlier in 2026 in China and much of Europe. The company has also received a notice of allowance from the Canadian Intellectual Property Office, pending final issuance, for the Canadian national-stage application of this family, thus providing protection across a broad swath of North America, Europe, and China.

Alexander Hurst, Chief Corporate Officer and General Counsel of Immunophotonics, commented, “Continued expansion of our intellectual property portfolio is central to Immunophotonics’s long-term strategy. This new U.S. patent broadens the protection surrounding our proprietary technology and adds another important layer to our growing patent estate as we advance IP-001 through clinical development and explore combinations with other immuno-oncology assets. As interest in immuno-oncology grows, we remain focused on advancing our clinical programs while strengthening the intellectual property foundation that underpins our lead asset.”

Robert Arch, Ph.D., Chief Executive Officer & President of Immunophotonics, added, “This patent marks another key step in our efforts to protect the innovation at the core of our approach to Interventional Immuno-Oncology®. Our lead asset, IP-001, is designed to retain tumor antigens liberated by tumor ablation at the site of injection to boost antigen presentation and immune cell activation to enable a systemic anti-tumor immune response. As we continue to evaluate IP-001 across multiple solid tumor indications, protecting the science and technology behind our platform is an important element in positioning us to fully realize the therapeutic potential of our approach for patients while generating value for our investors.”

About IP-001

IP-001 is a proprietary glycan polymer that generates tumor antigen depots and acts as a potent, multimodal immune stimulant intended to induce the patient’s immunological responses to eradicate cancer. IP-001 is designed to (1) prolong the availability of tumor antigens liberated by tumor ablation, (2) facilitate the recruitment and activation of innate immune cells, such as antigen-presenting cells (APCs), (3) increase the uptake of the tumor antigens into the APCs, and (4) promote an adaptive immune response against the tumor cells. Activation of a systemic, adaptive immune response allows immune effector cells to seek out and eliminate tumor cells throughout the body.


About Immunophotonics

Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology®. IP-001, which is the first asset from the company’s intellectual property platform, is currently assessed in multiple clinical trials and has the potential to overcome the immunosuppressive milieu of the tumor microenvironment to enable a tumor-specific immune response in patients with solid cancers. By combining routine energy therapies, such as ablation or radiation, with injection of its proprietary immunostimulatory drug candidates, including IP-001, Immunophotonics seeks to trigger a systemically active anti-tumor immune response that can destroy circulating tumor cells and micro-metastases left behind after a local ablation. The company’s world headquarters is in St. Louis, Missouri, USA, and its European headquarters is in Bern, Switzerland. For more information, visit www.immunophotonics.com.


Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements. Such statements involve inherent risks and uncertainties, and numerous factors could cause actual results to differ materially from those made or implied herein. All information provided in this press release is as of the date of this press release, and Immunophotonics, Inc. undertakes no duty to update such information, except as required under applicable law.

Public Relations
Immunophotonics, Inc.
+1 314-501-1919
IR@immunophotonics.com
Visit us on social media:
LinkedIn
Instagram
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Science Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.